Related Experiment Video
Updated: May 1, 2026
12:33
High-throughput Fluorometric Measurement of Potential Soil Extracellular Enzyme Activities
Published on: November 15, 2013
50.5K
[Not Available]
1Universitätsklinikum Charité, Berlin, Germany.
Summary
Rheumatoid arthritis treatment has advanced with biological therapies like TNF inhibitors, offering improved efficacy and safety over traditional DMARDs for severe cases. Ongoing research and committees monitor these potent new agents and their long-term effects.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Context:
- Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease causing joint destruction and extra-articular manifestations.
- Current treatments lack a definitive cure, necessitating advanced therapeutic strategies.
- Traditional Disease Modifying Antirheumatic Drugs (DMARDs) have limitations, particularly in refractory RA cases.
Purpose:
- To review novel biological agents for rheumatoid arthritis treatment.
- To discuss the efficacy and safety profiles of new cytokine inhibitors.
- To present current treatment recommendations and cost-benefit analyses for biologicals in RA.
Summary:
- Biological therapies, including tumor necrosis factor (TNF) α- and interleukin (IL) 1-inhibitors (e.g., infliximab, etanercept, anakinra), demonstrate superior efficacy and safety compared to conventional DMARDs.
- These advanced agents are particularly beneficial for patients with refractory rheumatoid arthritis.
- International and national committees are established to oversee the use of these new agents and monitor potential long-term effects.
Impact:
- Biologicals represent a significant advancement in managing rheumatoid arthritis, offering new hope for patients with severe or refractory disease.
- The development of targeted cytokine inhibitors provides a more precise approach to controlling RA-associated inflammation.
- Establishing regulatory frameworks and cost-benefit analyses is crucial for the responsible integration of these potent therapies into clinical practice.
